<Suppliers Price>

Ketorolac tromethamine

Names

[ CAS No. ]:
74103-07-4

[ Name ]:
Ketorolac tromethamine

[Synonym ]:
Ketorolac tromethamine
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
2-amino-2-(hydroxymethyl)propane-1,3-diol,5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid - 2-amino-2-(hydroxymethyl)propane-1,3-diol (1:1)
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
Ketorolac tris salt
rac Ketorolac Tromethamine Salt
(±)-Ketorolac Tromethamine Salt
MFCD00887595
5-(Phenylcarbonyl)-2,3-dihydro-1H-pyrrolizin-1-carbonsäure--2-amino-2-(hydroxymethyl)propan-1,3-diol(1:1)
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid - 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)
1,3-Dihydroxy-2-(hydroxymethyl)propan-2-aminium 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylate
Ketorolac (tromethamine salt)

Biological Activity

[Description]:

Ketorolac tromethamine salt is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2.

[Related Catalog]:

Research Areas >> Inflammation/Immunology

[Target]

COX-1:20 nM (IC50)

COX-2:120 nM (IC50)


[In Vitro]

Ketorolac is a non-steroidal anti-inflammatory agent, acting as a nonselective COX inhibitor, with IC50s of 20 nM for COX-1 and 120 nM for COX-2[1].

[In Vivo]

Ketorolac tromethamine (0.4%) causes nearly complete inhibition on LPS endotoxin-induced increases in FITC-dextran in the anterior chamber, and increases in aqueous PGE2 concentrations in the aqueous humor in rabbits[1].Ketorolac (30 mg/kg, i.v.) rapidly reverses hyperalgesia in rats. Ketorolac also reduces carrageenan-induced hyperalgesia and paw PG production, and causes reduction in PGE2 levels in rats[1]. Ketorolac (4 mg/kg/day, p.o.) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats[2]. Ketorolac (60 μg/10 μL) reduces the histological changes such as ischemic cell death, including cytoplasmic eosinophilia with disintegration of cytoarchitecture and nuclear pyknosis in rats. Ketorolac also effectively reduces neuronal death and improves hindlimb motor function, and the long-term survival is similar to that in the control group[3].

[Animal admin]

Rats[2] Treated rats receive oral doses of 1 mL aqueous solution of paracetamol (80 mg/kg/rat/day), Ketorolac (4 mg/kg/day) or etoricoxib (10 mg/kg/day) administered by gavage from the day of surgery until death, 2 weeks later. Control rats receive tap water (1 mL/day by gavage). The animals are housed under climate-controlled environment (12 h light/12 h dark, 20-24ºC) with free access to standard laboratory chow and tap water[2].

[References]

[1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.

[2]. Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18(6):630-4.

[3]. Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100(4):1134-9.


[Related Small Molecules]

4-Acetamidophenol | Aspirin | Paradol | Ginsenoside Rg3 | Ginsenoside Compound K | Xanthohumol | Ibuprofen | Diclofenac | NS-398 | Meloxicam | Flufenamic Acid | Epicatechin | Salicylic acid | ketoprofen | Naproxen

Chemical & Physical Properties

[ Boiling Point ]:
493.2ºC at 760 mmHg

[ Melting Point ]:
160-161ºC

[ Molecular Formula ]:
C19H24N2O6

[ Molecular Weight ]:
376.404

[ Flash Point ]:
252.1ºC

[ Exact Mass ]:
376.163422

[ PSA ]:
146.01000

[ LogP ]:
0.65210

[ Storage condition ]:
Hygroscopic, Refrigerator, Under Inert Atmosphere

[ Water Solubility ]:
H2O: 15 mg/mL stable at least one month at −20 °C., soluble

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UY7759900
CAS REGISTRY NUMBER :
74103-07-4
LAST UPDATED :
199712
DATA ITEMS CITED :
6
MOLECULAR FORMULA :
C15-H13-N-O3.C4-H11-N-O3
MOLECULAR WEIGHT :
376.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
15 mg/kg/6D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - changes in potassium Nutritional and Gross Metabolic - body temperature increase
REFERENCE :
AIMDAP Archives of Internal Medicine. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1908- Volume(issue)/page/year: 153,1000,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
19853 ug/kg/12D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
REFERENCE :
APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 27,1055,1993
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
857 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate increase, without fall in BP Vascular - BP lowering not characterized in autonomic section Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
REFERENCE :
JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 32,305,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
8400 ug/kg/3D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic - changes in potassium
REFERENCE :
AJKDDP American Journal of Kidney Diseases. (Grune & Stratton, Inc., Journal Subscription Dept., POB 6280, Duluth, MN 55806) V.1- 1981- Volume(issue)/page/year: 24,578,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1200 ug/kg
TOXIC EFFECTS :
Behavioral - hallucinations, distorted perceptions Lungs, Thorax, or Respiration - bronchiolar constriction Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
SMJOAV Southern Medical Journal. (Southern Medical Assoc., POB 2446, Birmingham, AL 35205) V.1- 1908- Volume(issue)/page/year: 87,282,1994
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
858 ug/kg
TOXIC EFFECTS :
Cardiac - pulse rate increase, without fall in BP Lungs, Thorax, or Respiration - dyspnea Immunological Including Allergic - anaphylaxis
REFERENCE :
APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 26,1237,1992

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301-H315-H319-H335

[ Precautionary Statements ]:
P261-P301 + P310-P305 + P351 + P338

[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges

[ Hazard Codes ]:
T:Toxic

[ Risk Phrases ]:
R25;R36/37/38

[ Safety Phrases ]:
S26-S45

[ RIDADR ]:
UN 2811

[ WGK Germany ]:
3

[ RTECS ]:
UY7759900

[ Packaging Group ]:
II

[ Hazard Class ]:
6.1(a)

[ HS Code ]:
2942000000

Customs

[ HS Code ]: 2942000000

Articles

Topical cyclosporine a 1% for the treatment of chronic ocular surface inflammation.

Eye Contact Lens 40(5) , 283-8, (2014)

To evaluate the use of topical cyclosporine A (CsA) 1% emulsion in the treatment of chronic ocular surface inflammation (OSI).We conducted a retrospective chart review of patients with various forms o...

Ketorolac eye drops reduce inflammation and delay re-epithelization in response to corneal alkali burn in rabbits, without affecting iNOS or MMP-9.

Arq. Bras. Oftalmol. 78 , 67-72, (2015)

To assess the effects of 0.5% ketorolac tromethamine without preservatives on the expression of iNOS and MMP-9 in alkali burn ulcers.Twelve eyes of 120-day-old male rabbits were treated (TG) every 6 h...

Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals.

Pharmacotherapy 10(6 ( Pt 2)) , 33S-39S, (1990)

In humans, ketorolac is completely bioavailable and its kinetics are linear. It is absorbed rapidly (half-life for absorption 3.8 min) after oral (fasting) and intramuscular administration; food delay...


More Articles


Related Compounds